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Since the early report of Lee et a! [1] describing a
vasoactive acidic lipid in the rabbit renal medulla,
the kidney has been recognized as a major site of
prostaglandin metabolism in the body. In fact, the
kidney medulla is one of the richest sources of
cyclooxygenase activity and, therefore, has been
widely used for prostaglandin biosynthetic studies.
Many direct and indirect findings have established
that PG!2 and PGE2 play important roles in the
regulation of renal blood flow and maintenance of
electrolyte balance. Other oxygenated metabolites
of arachidonic acid (that is, PGF2a, PGD2, TXB2,
hydroxyeicosatetraenoic acids, and leucotrienes
[2]) are reportedly synthesized by the kidney, al-
though their function remains as yet undefined.
Tissues do not store prostaglandins but generate
them from endogenous substrate fatty acids on
demand. Several peptide hormones including bra-
dykinin and angiotensin II are able to activate renal
phospholipase and release arachidonic acid for
prostaglandin synthesis. The action of prostaglan-
dins is usually limited to their site of biosynthesis
because powerful prostaglandin dehydrogenases
are present, particularly in the lung, that inactivate
the PG's before their removal from circulation.
The kidney is also an important organ for prosta-
glandin excretion. It accumulates exogenous pros-
taglandins above the plasma level [3] and is respon-
sible for removing 50 to 80% of the body's prosta-
glandins by the urinary route, although very little is
yet known about specific mechanisms. This article
will present a brief review of the recent information
on the biosynthesis and metabolism of renal prosta-
glandins. For a more extensive discussion, we
Received for publication December 11, 1980
0085-2538/81/0019-0760 $02.20
©1981 by the International Society of Nephrology
760
recommend that the reader consult the reviews
published elsewhere [4—6].
Prostaglandin biosynthesis
The renal prostaglandin biosynthesis has been
extensively investigated for over a decade [7—9], but
there are still many gray areas of ambiguity. In
vitro, the renal papilla and medulla from rat, rabbit,
and human [7-46] contain more cyclooxygenase
(prostaglandin endoperoxide synthetase) than the
cortex does. The medullary cyclooxygenase is
membrane bound and can be solubilized and isolat-
ed by column chromatography [14]. The solubilized
enzyme has a heme-dependent cyclooxygenase ac-
tivity that converts arachidonic acid to the hydro-
peroxide PGG2 and a peroxidase activity that con-
verts PGG2 to PGH2. The overall process is stimu-
lated by phenolic compounds, but is inhibited by
nonsteroidal antiinflammatory agents. In vivo, the
activity is probably limited by substrate availability
[17—2 1]. Experiments with cx vivo isolated perfused
rabbit kidneys [19—21] have shown that bradykinin
and angiotensin II, which stimulated phospholipase
activity, lead to increased PGE2 release. Similar
experiments with rat papilla slices [17] or isolated
renomedullary interstitial cells [18] in vitro or dog
kidney in vivo [221 have yielded similar findings.
Anatomically, the cyclooxygenase-containing
cells in the kidney of several species have been
located by an immunofluorescence procedure [23—
25]. In all species, the enzyme was found in the
epithelial cell of the cortical and medullary collect-
ing ducts, arterial vascular endothelial cells, and
medullary interstitial cells. Other sites containing
cyclooxygenase include the parietal layer of Bow-
man's capsule in rabbit, mesangial cells in ovine
and bovine glomeruli, and the thin limbs of Henle's
ioop in the hydronephrotic rabbit kidney. Some of
these cells or structures have been isolated and
their PG synthetases studied by biochemical meth-
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ods. In this respect, interstitial cells from rat and
rabbit [18, 26, 27] have been reported to produce
PGE2 and PGF2,. Terragno, McGiff, and Terragno
[281 demonstrated that the arteries and arterioles
isolated from pig kidney cortex by microdissection
have a high capacity for PG!2 biosynthesis. Bohman
[29] and Grenier and Smith [30] have reported that
the collecting duct epithelial cells isolated from
rabbit renal papilla synthesized 6-keto-PGF1,
PGF2a, PGE2, and PGD2. Other groups [3 1—33]
have shown that the isolated glomeruli from rat
kidney cortex have the capacity for synthesis of
PGF2a, PGE2, 6-keto-PGF1a, thromboxane B2, and
PGD2. The mesangial cells [34] and the epithelial
cells [351 are the site of prostaglandin E2 biosynthe-
sis, and the arterioles probably produce PGI2,
whereas the cortical tubule fragments [311 contain
much lower activity than do the glomeruli.
The literature shows qualitative and quantitative
inconsistencies in prostaglandins produced in dif-
ferent regions of the kidney. Whorton et al [15]
demonstrated clear evidence that rabbit kidney
cortex microsomes synthesized both PGI2 and
PGE2 from arachidonic acid and PG endoperoxide,
whereas the medullary microsomes synthesized ex-
clusively PGE2. Similar experiments with rat inner
medullary slices [36] or rabbit medulla microsomes
[14] agreed with these results. New evidences,
however, extended these observations and showed
that the medulla also had the capacity of synthesiz-
ing PG!2. Silberbauer and Sinzinger [37] found that
both cortex and medulla of rat generated prostacy-
din-like activity blocking platelet aggregation and
that the medulla was significantly more active than
the cortex. With a gas chromatography mass spec-
trometry method, Oliw et al [38] found high levels
of 6-keto-PGF1a accumulated in cortex, medulla,
and papilla of postmortem rabbit kidney. Although
the papilla 6-keto-PGF1a level was the highest, the
cortex contained five times more 6-keto-PGF1a than
did PGE2 and PGF2a. Very recently, Hassid and
Dunn [16] reported that microsomes prepared from
both cortex and medulla of human kidney convert-
ed arachidonic acid to PGF2a, 6-keto-PGF1a, TXB2,
and PGE2 and that the relative abundances were
similar in both regions. They concluded that there
was no compartmentalization of PG!2 synthetase in
the cortex.
We feel these inconsistencies arose from differ-
ences in the in vitro experimental conditions. The
medulla cortex and papilla probably contain isomer-
ases for the production of PGE2 and PG!2. The two
enzymes, however, have wider differences in sub-
strate affinity [39] and cofactor requirements [40].
Therefore, any difference in substrate concentra-
tion, incubation time, or the presence of cofactors
used in each study may lead to differences in
prostaglandin product distribution. Furthermore,
prostaglandin endoperoxides are extremely unsta-
ble. If the cyclooxygenase in an enriched tissue
such as kidney medulla is allowed to operate at
optimal condition, the endoperoxide generated may
be more than its isomerases can consume. The
excess will randomly decompose to PGF2a, PGE2,
and PGD2. Our in vitro study described below best
illustrates this situation.
When a piece of rabbit inner medulla was homog-
enized with '4C-arachidonate and incubated for 5
mm, the formation of radioactive prostaglandin
products varied with the substrate concentration
(Fig. 1). If the exogenous arachidonic acid was
sufficiently low (2 pM) the product was almost
exclusively PGE2. If larger amounts (0.1 #.LM) of
substrate were added or the cyclooxygenase was
stimulated by phenolic compounds, the products
were PGE2, PGF2a, and PGD2. Addition of reduced
glutathione increased PGE2 at the expense of PGF2a
and PGD2. These results suggest that the enzymatic
product in the medulla is PGE2, and the rate-
limiting step is the PGE2 isomerase. When the
cyclooxygenase is artificially stimulated, any ex-
cess endoperoxide decomposes into a variety of
mixed prostaglandin products. But if the isomerase
is stabilized with reduced glutathione, the enzyme
can handle additional amounts of endoperoxide.
Throughout this study, the formation of 6-keto-
PGF1, was not detected.
A small amount of 1 l-hydroxyeicosatetraenoic
acid (1 1-HETE) was detected in the extract and its
identity was confirmed by GCMS analysis. This
confirmed a similar finding of Hamberg [7]. The 11-
HETE was not a product of lipoxygenase because
its formation can be inhibited by indomethacin. It is
probably a side product of the cyclooxygenase as
suggested by Porter et al [411.
Similar experiments with cortex slices yielded
smaller amounts of prostaglandins. With either low
or high substrate concentration, the cortex pro-
duced four times less prostaglandins than did the
medulla. PGE2 and PGF2a were the main products,
and very little 6-keto-PGF1a was detected.
Although these results agreed with earlier report-
ed work, we suspected that the PG!2 synthetase in
our preparation was being inactivated by the organ-
ic peroxides generated during vigorous tissue ho-
mogenation in air. Therefore, we prepared washed
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Fig. 1. Radiochromatogram of the extract from the conversion of'C-arachidonic acid to prostaglandins by rabbit kidney homogenate: a
medulla 1.0 g of tissue and 2 LM AA, b cortex 1.0 g of tissue and 2 I.LM AA, c medulla 0.1 g of tissue and 100 IJ.M AA, and d medulla 0.1 g
of tissue, 100 ILM AA, and I m reduced glutathione.
microsomes from both rabbit cortex and medulla
under an argon atmosphere. Indomethacin was also
added to stop PG biosynthesis. These microsomes
were incubated with various concentrations of '4C-
PGH2, and the products were analyzed by thin-
layer chromatography (Fig. 2).
At the lowest PGH2 concentration (0.4 pM), the
medulla and cortex microsomes both produced
abundant amounts of 6-keto-PGF1. The yield of
PGF2a, PGE2, and PGD2 were identical to the heat-
inactivated enzyme control. Addition of reduced
glutathione to the medulla microsome reaction sig-
nificantly increased the yield of PGE2, whereas in
the cortex case it increased PGF2a. Figure 3 illus-
trates the effect of increasing the PGH2 concentra-
tion on the activities of cortical and medullary PGI2
synthetase and the glutathione-dependent medul-
lary PGE2 isomerase. Both prostacyclin synthetase
reactions follow a hyperbolic pattern and approach
saturation as PGH2 concentration reaches 10 .LM.
Medullary PGE2 synthesis continued to increase
with increasing PGH2 concentration beyond 15 .LM,
suggesting that the Km values for the two enzymes
are different. At all substrate concentrations, the
yield of 6-keto-PGF1a from medullary microsome
was three to four times greater than the cortex
microsome was.
Therefore, it is clear that the PGI2 synthetase in
the kidney is sensitive to harsh tissue handling.
Unprotected homogenization and cell fractionation
probably activate cyclooxygenase and generate or-
ganic peroxides that inactivate PGI2 synthetase. If
properly protected, the in vitro measurement of
PGI2 biosynthesis in microsomes corresponds very
well with the results from tissue slices [37] or
postmortem accumulation of PGI2 in vivo [381. It
should be noted that the difference in PGI2 synthe-
tase activities between cortex and medulla parallels
closely their cyclooxygenase activities.
To assess the classical prostaglandins formed
enzymatically from PGH2 requires a precise com-
parison between active microsome and its heat-
inactivated control. The amounts of prostaglandin
E2, D2, and F2 formed after incubation of PGH2
Medulla
2 nmole AA Medulla1000 nmole AA
F
6KF
Cortex b
2 nmole AA
6KF
Medulla d
1000 nmole AA
+ glutathione
E
6KF 6KF
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Fig. 2. Radiochromatogram of the extract from the conversion of '4C-PGH2 (0.44 M) to prostagiandins by rabbit kidney microsome
prepared in the presence of 0.1 mi indomethacin and under the atmosphere of argon: a medulla 1 mg/kg, b medulla I mg/mi, 1 mM
reduced glutathione, c cortex 4 mg/mi, and d cortex 4 mg/mi, 1 mrei reduced glutathione.
with heat-inactivated enzyme were substracted
from the active microsome products. After this
correction, only the glutathione-dependent PGE2
synthesis in the medulla and glutathione-dependent
PGF2a synthesis in the cortex appeared to be cata-
lyzed by enzymes. We have developed a simple
assay to measure the medullary PGE isomerase
activity. Labeled PGH2 was incubated with medulla
microsome for 30 seconds, and the reaction was
quenched by the addition of ferrous chloride to
convert unreacted PGH2 to HHT. The yield of
PGE2 is measured by radio thin-layer chromatogra-
phy. In this assay, the reduced glutathione is an
essential cofactor. The requirement can be replaced
by the high-speed supernatant from renal medulla,
indicating the presence of endogenous cofactors.
But, the requirement cannot be fulfilled by cys-
teine. In contrast to the PGI2 synthetase, the PGE2
isomerase is not inhibited by azo analog I (U-
51,605). The properties of the renal PGE2 isomerase
appear to be quite similar to the PGE2 isomerase
isolated by Ogino et al [401 from bovine vesicular
gland.
The data clearly indicate that PGE2 and PGI2 are
the principal cyclooxygenase products in normal
rabbit kidney. The formation of PGD2 and a great
portion of PGF2a were decomposition products of
excess endoperoxide in an in vitro heterogenous
surrounding. The distribution of PGI2 synthetase
parallels the distribution of cyclooxygenase in vari-
ous regions of the kidney. It is possible that the
endoperoxide metabolizing enzymes are coupled
with specific cyclooxygenase for efficient and rapid
conversion of the released arachidonic acid to a
specific product [211.
Prostaglandin catabolism
The kidney possesses enzymatic activities for
essentially every major step of prostaglandin catab-
olism. These reactions include C-iS oxidation, 13
Medu la
C
Cortex
b
Medulla
+ glutathione
d
Cortex
+ glutathione
6KF
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Fig. 3. Effect of substrate concentrations on the formation of
PG!2 and PGE2 (glutathione dependent) by rabbit renal medul-
lary microsome and PG!2 by rabbit renal cortical rnicrosorne—l
ml of microsome (0.8 mg/rn/for medulla and 4 mg/rn/for cortex)
with various concentrations of'4C-PGH2 for! mm at 370 C. The
products were extracted and analyzed by thin layer chromatog-
raphy (organic layer of EtoAC:HAc: 2,2,4-trimethyl pen-
tane:H,0, 110:20:50:100).
reduction, p-oxidation, o-hydroxylation, and inter-
conversion of hydroxyl and keto groups at C-9.
Most of the knowledge was obtained by in vitro
experimentation with tissue homogenate. Little in-
formation exists on the roles of kidney as a metabol-
ic organ in vivo.
Four types of prostaglandin oxidoreductases
have been found in the high-speed supernatant of
kidney homogenate. Their properties are summa-
rized in the following sections.
(1) Type I 15-hydroxy prostaglandin dehydrogen-
ase (PGDH). The type I PGDH catalyzes the first
step of prostaglandin inactivation. It occurs most
abundantly in the cortex [42], and histochemical
staining has located the enzyme in the proximal and
distal tubules [43, 441. Renal PGDH from rat [45],
chicken [46], pig [47], and monkey have been
purified, and multiple species have been detected
for the chicken enzyme. The enzyme catalyzes the
oxidation of the 15(S) hydroxyl group of the E, F,
A, and I series of prostaglandins to their 15-keto
derivative. PGB, PGD, 6-keto-PGF1 or thrombox-
ane B2 are poor substrates. In contrast to the type II
PGDH, the type 1 enzyme has a very rigid substrate
specificity and the reaction is essentially irrevers-
ible.
The tubular location of the renal PGDH plus the
fact that the enzyme does not act on circulating
prostaglandins (see later sections) suggests that the
enzyme may play a role as a regulator of intrarenal
prostaglandin activities. In this connection, it is
interesting to note that the diuretic action of furose-
mide and ethacrylic acid has been related to their
inhibition of renal PGDH [45, 46]. In the hyperten-
sive rat, the activity of renal PGDH was significant-
ly lower than that of the normotensive control [48].
This finding has been related to the increased
vascular resistance in the hypertensive animals.
Renal PGDH also has a short life span, and its
replacement depends on de novo protein synthesis
[491. Presumably its activity could be controlled by
blood-born factors that affect protein synthesis.
(2) Type ii prostaglandin dehydrogenase. Type
II PGDH is a relatively nonspecific enzyme catalyz-
ing the reversible interconversion of hydroxyl and
keto functions at both C-9 and C-iS. Previously
described as two separate enzymes, 9-keto reduc-
tase and NADP-dependent 15-hydroxy prosta-
glandin dehydrogenase, it now appears that the two
activities are associated with a single protein spe-
cies. The enzyme has been purified from the kid-
neys of swine [50, 51], chicken [46], rabbit [52], and
monkey (Sun and Cray, unpublished findings), as
well as other organs or tissues from a number of
species. In most cases, the enzyme existed in
several molecular forms that can be resolved by
isoelectric focusing. The cofactor requirement is
NADP, and the enzyme is fully reversible at both
the C-9 and the C-IS position. The substrate speci-
ficity of the partially purified monkey kidney type II
PGDH is summarized in Table 1. Despite the appar-
ent broad specificity, the enzyme will not reduce
the 1 1-keto of PGD2. In a recent study of Chang and
Tai [50], a purified swine kidney type II PGDH
preparation failed to reduce 6-keto-PGF1. The
higher activities of 15-methyl PGE2 and 16,16-
dimethyl PGE2 suggested that the reaction centers
at C-9 and C-IS might compete with each other for
the same active site on the enzyme surface. Elimi—
nation of the C-IS reaction facilitates the reaction of
C-9. The specificity apparently is not confined to
prostaglandin moieties because the enzyme also
5.0 10.0 15.0
PGH2 added, X 10 M
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Table 1. Substrate specificity of purified type II PGDH from
monkey kidney
Relative activity
catalyzed the rapid reduction of 5a-dihydrotestos-
terone in the presence of NADPH, arid the steroid
reductase activity cannot be separated from the PG
reductase activity throughout the purification. The
results suggest that the same enzyme may be re-
sponsible for the oxidation-reduction of both types
of molecules.
The type II PGDH occurs in both cortex and
medulla [51] of the swine kidney. It has a much
lower affinity for prostaglandins than the type I
enzyme does. Apparent Kms for reduction of 9-
keto group of PGE2 are 400 LM for enzyme from
both rabbit [521 and monkey (Sun and Cray, unpub-
lished findings). The swine kidney type I PGDH
binds to the PG-attached sepharose whereas type II
does not [53]. But, the reactions catalyzed by the
type II PGDH were observed in in vivo prostaglan-
din metabolism [54, 551. Increased 9-keto reductase
levels were reported in the kidney of chronically
salt-loaded rabbits [561. The idea remains viable
that the enzyme may be another site for regulating
prostaglandin activity.
(3) 15-Keto prostaglandin z'3-reductase. In as-
sociation with the type I PGDH, the 13 reductase
reduces the & double bond of the l5-keto prosta-
glandins to the 13,14-dihydro 15-keto prostaglan-
dins. The cofactor can be either NADH or
NADPH, and the reaction is irreversible. The en-
zyme is specific for the 15-keto prostaglandins of
the E, F, D, and I series and probably the 15-keto
thromboxane B2. It does not catalyze the reduction
of their corresponding 15-hydroxyl prostaglandins.
The enzyme has been purified from bovine lung [57]
and human placenta [58] but the renal enzyme has
not been studied in detail.
(4) 9-Hydroxy prostaglandin dehydrogenase.
This is a unique enzyme different from the type II
PGDH. It was found in the cortex of kidneys of rat
[59] and rabbit [60]. The enzyme catalyzes the
oxidation of 9ct-hydroxyl groups of prostaglandin
F2a and Fia, but not 6-keto-PGF1c. or PGF2. The
significance of this conversion is unclear.
It should be mentioned that a separate 9-hydroxyl
PGDH [61] was detected in rabbit liver and human
platelet. The enzyme oxidizes 6-keto-PGF1a to the
biologically active molecule 6-keto-PGE1. The kid-
ney apparently contains little of this enzyme.
The presence of fatty acid w and w-1 hydroxyl-
ation system in kidney cortex microsome of rat and
pig has been demonstrated [62], although little work
has been reported. The n-oxidation of fatty acid is a
universal process occurring in all major organs
including the kidney.
In vitro studies
A number of studies have been conducted to
examine the prostaglandin metabolism in crude
kidney homogenate. In most in vitro studies, the
reaction mixture is fortified with pyridine nucleo-
tides [63—65]. The direction of the metabolic se-
quence was thus determined by the cofactor added.
Therefore, incubation of labeled PGE2, PGF2. or
PGI2 with kidney supernatant of rat and rabbit in
the presence of NAD gave predominantly their
13,14-dihydro 15-keto metabolites. But, if NADPH
were added, PGE2 would be reduced to PGF2. This
indicates that the direction of PG catabolism in vivo
is a function of intracellular pyridine nucleotide
ratio and their redox state. Moreover, species dif-
ferences exist in the levels and activities of various
cytoplasmic enzymes. Hoult and Moore [64] stud-
ied the oxidative metabolism of PGF2a in kidney
supernatants of rat, rabbit, guinea pig, and pig and
found the metabolites were both qualitatively and
quantitatively different. The major product was
13,14-dihydro-15-keto PGF2a, but the rat also oxi-
dized the dihydro keto PGF2 to dihydro keto PGE2
whereas guinea pig and pig reduced it to dihydro
PGF2a. Only in the rabbit were substantial amounts
of PGF2a oxdized directly to PGE2. The metabolic
reaction sequence is summarized in Fig. 4.
Ex vivo studies
Despite the extensive studies of prostaglandin
metabolism in vitro, little information is published
Reduction NADPH as cofactor
PGE2
PGE1
PGD1
PGD2
PGF2,
PGA2
PGB2
15-Keto dihydro PGF2.
15-Keto PGF2
15-Methyl PGE2
16,16-Dimethyl PGE2
Sct-Dihydro testosterone
Oxidation NADP as cofactor
PGF2
PGE2
PGE1
16, 16-Dimethyl PGE2
15-Methyl PGE2
100
62 to 70
0
0
0
48 to 59
24 to 34
56 to 90
20 to 68
143 to 244
143 to 230
150 to 400
332
100
160
0
0
NADPH
Fig. 4. In vitro prostaglandin (PG) metabolism by rabbit kidney supernatant. The direction of PG metabolism may be a function of
intracellular pyridine nucleotide ratio and their redox state.
on the fate of renal prostaglandins in vivo, particu-
larly the events involved in the renal handling of
circulating prostaglandins. PGE2 and PGF2a inject-
ed into the renal artery of the isolated perfused
rabbit kidney are filtered through the glomerulus
and secreted by the tubules 166—681. The latter
process is mediated by the organic anion transport
system and can be blocked by indomethacin, pro-
benecid, or bromocresol green. Significant metabo-
lism does occur during the tubular transport. Pros-
taglandin E2 is also absorbed by the loop [69] of
Henle and the distal tube in the rat. The intact
prostaglandins found in the urine are believed to be
of renal origin [70], with the point of entry most
likely Henle's loop [711.
We have investigated the prostaglandin renal
metabolism in an ex vivo perfused rabbit kidney
preparation. The method of Schurek et al [721 was
modified for rabbit kidneys, and the prostaglandins
were delivered at a rate of 10 p.g/min during a single-
pass perfusion. The venous effluent and in some
cases urine samples were collected separately and
analyzed.
When multiple tritium labeled PGE2 was infused
into the perfused kidney, 80 to 85% of the injected
radioactivity was recovered in the perfusate. The
perfusate was passed through an Amberlite XAD-2
column. Seventy-five to eighty percent of radioac-
tivity was extractable as lipid material, and the
remaining radioactivity was water soluble material
or tritiated water. The metabolites were separated
by high-performance liquid chromatography and
analyzed by gas chromatography-mass spectrome-
try. In the perfusate, unmetabolized PGE2 was 16 to
31% whereas the major metabolite was the tetranor
PGF (Fig. 5). The formation of the tetranor PGF
from PGE2 involves f3-oxidation and reduction of
the keto group at C-9. A small amount of tetranor
15-keto dihydro PGF was also found, which indicat-
ed that the 15-PGDH and reductase routes were
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"COOH 69-84%
-
- conversion
OH OH
PGE2
>90%
+
OH OH 30%
of minor importance. The metabolic profile was
unchanged by increasing the cytosolic pyridine nu-
cleotide oxidation potential by adding pyruvate and
red blood cells [73] to the perfusion fluid. There-
fore, the extensive reduction of the 9-keto group
probably was not a result of anoxia-induced reduc-
tion of pyridine nucleotide.
Extensive 13-oxidation was also observed for
PGF2a and PGI2. Consistent with the PGE2 study,
the 15-PGDH products in venous effluent were
scarce or absent. PGF2c. was almost completely
(97%) converted to tetranor PGF10 during a single
pass. No PGE metabolites were detected, indicat-
ing that the 9-hydroxydehydrogenase was not oper-
ating. PGI2 was more resistant to 13-oxidation, form-
ing only 30 to 50% dinor metabolites. Apparently
the cyclic enol ether or the 6-keto functional groups
retarded 13-oxidation. In contrast to our previous
report [74], we found that the 15-PGDH product
9,1 l-dihydroxy-6, 15-diketo-2,3-dinor PGF10 was
only a minor product in the vascular perfusate;
sometimes less than 5% of the total perfu sate radio-
activity.
Because it is unlikely that large amounts of intact
prostaglandins would be delivered to the kidney for
metabolism, we also examined the kidney handling
of major circulating prostaglandin metabolites. Ra-
diolabeled 13,14-dihydro-l5-keto PGE7 and 13,14-
dihydro- I 5-keto PGF20 were infused into the rabbit
kidney and the metabolic products analyzed by gas
chromatography mass spectrometry (Fig. 6). For
these compounds, the overall metabolic conversion
(63 to 64%) was less than their parent compounds.
Perhaps the metabolites were not efficiently trans-
ported from vascular compartment into the cells.
The metabolites from 15-keto-dihydro-PGE2 were
tetranor dihydro PGE1, tetranor dihydro PGF, and
tetranor dihydro 15-keto PGF. For 15-keto dihydro
PGF20, the metabolites were tetranor dihydro
PGF10 and tetranor dihydro l5-keto PGF10. It ap-
Trace
+
PG F20
HOOC
OH
PG 12
—1.2%
OH
>90%
OH
OH
OH OH 60%
Fig. 5. Proposed metabolic pathways of PGE2, PGF2, and PG!2 in isolated perfused rabbit kidney. The stereo configuration of C-9
hydroxyl from reduction of PGE2 has not been determined.
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0
15-keto dihydro PGE2
64%
10%
+:ss:c;OH
OH°
63%
OH0H
+
0
15-Keto dihydro PGF20 50%
+ unknown - 20%
Fig. 6. Proposed metabolic pathways of 12,14-dihydro-15-keto-PGE2 and /3,14-dihydro-15-keto-PGF2, in isolated perfused rabbit
kidney. The stereo chemistry of reduction of C-9 or C-IS keto groups have not been determined.
pears that both C-9 and C-iS keto groups are
susceptible to reduction. As we discussed in the
previous section, the nonspecific type II PGDH can
interconvert hydroxyi and keto functions at both
the C-9 and C-IS positions.
The metabolite pattern of PGF2 in rabbit kidney
compared favorably with that obtained from rabbit
urine after i.v. PGF2c. administration. Svanborg and
Bygdeman [55] reported that tetranor PGF1a, te-
tranor dihydro PGF10, and tetranor dihydro 15-keto
PGF1 counted for two thirds of recovered urinary
radioactivity from PGF2a-treated rabbit. In addi-
tion, the reduction of 9-keto groups of the E prosta-
giandins in vivo has been reported in man [541. Only
PGI2 showed a trace of w-hydroxylation. Therefore,
w-hydroxylation of prostaglandins, if occurring at
all, must be of minor importance.
Summary. We found the kidney to be a major site
of prostaglandin metabolism. The circulating pros-
taglandins in the vascular compartment are exten-
sively graded by the mitochondrial 13-oxidation sys-
tem to shorter chain compounds. The keto groups
at C-9 and C-IS are reduced to alcohol. The 15-
PGDH plays only a minor role in the handling of
circulating prostaglandins. The purpose for exten-
sive renal degradation is probably to provide these
nonpolar lipids with greater water solubility so that
they can be easily excreted by the urinary route. It
may also be used as a fatty acid for generating
metabolic energy. The physiologic roles of the type
I PGDH are puzzling. We hypothesize that the
enzyme may be reserved for metabolic control of
intrarenal prostaglandin activities. The study of the
fate of endogenous renal prostaglandins should give
some insight into this important question.
Reprint requests to Dr. F. F. Sun, Department of Experimen-
tal Biology, The Upjohn Company, Kalamazoo, Michigan
49001, USA
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